Form 4: ABEONA Legal Officer Sells Shares for Tax Obligations

ABEONA Therapeutics' SVP, Chief Legal Officer, Brendan M. O'Malley, sold 13,578 shares of common stock on January 22, 2026, to cover tax obligations from restricted stock vesting.

Summary

• Brendan M. O'Malley, SVP, Chief Legal Officer of ABEONA THERAPEUTICS INC., reported a sale of common stock.
• The transaction involved 13,578 shares of ABEONA common stock.
• The shares were sold on January 22, 2026, at a weighted average price of $5.3309 per share, with prices ranging from $5.33 to $5.38.
• The sale was executed to cover tax obligations arising from the vesting of restricted stock awards.
• Following this transaction, Mr. O'Malley beneficially owns 451,134 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale by an executive to cover tax obligations related to equity compensation, executed under a pre-arranged 10b5-1 plan. It does not reflect a change in management's outlook or confidence in the company.

Positives

• The sale was non-discretionary, executed to cover tax obligations from restricted stock vesting, indicating the executive is receiving equity compensation.
• The transaction was pre-planned under a Rule 10b5-1 plan, which helps mitigate concerns about opportunistic insider selling.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases their direct equity alignment with shareholders.

Risks

• No specific new risks are introduced by this routine tax-related sale; the general risks associated with the company's operations remain.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

Industry Context

This is a routine insider transaction, common for executives receiving equity compensation, and does not inherently reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations upon the vesting of restricted stock awards are a standard practice across industries and are generally not viewed as discretionary selling.
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance practice, providing an affirmative defense against insider trading allegations by pre-scheduling trades.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary sale for tax purposes and does not signal a change in company fundamentals or management confidence.

Next Steps

• No specific future actions, events, or milestones are mentioned in this filing.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by a senior executive to cover tax liabilities associated with the vesting of restricted stock awards, executed under a pre-arranged 10b5-1 plan. Such transactions are common and do not typically signal a change in the company's fundamentals or management's confidence. Therefore, it provides no new information that would warrant a change in an investor's current position on the stock.

Keywords

ABEONA Therapeutics, ABEO, Form 4, insider trading, stock sale, tax obligations, restricted stock, Brendan O'Malley, 10b5-1 plan